AiFD Vice Chairman Engin Guner On Price Cuts In Turkey And Mounting Pressure On Industry: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive SummaryA former law maker and leader of the Turkish parliamentary delegation to the Council of Europe, Engin Guner knows about how policy works. The vice chairman of the Association of Research-Based Pharmaceutical Companies (AiFD), which represents Big Pharma in Turkey, emphasizes that government price cuts and related policy challenges, combined with currency depreciation, are taking a heavy toll on the industry.
You may also be interested in...
IEIS Secretary General Turgut Tokgoz On The Future Of Turkish Pharma: An Interview With PharmAsia News (Part 2 of 2)
In the midst of negotiations over the government’s next pharmaceutical budget, the leader of the Pharmaceutical Manufacturers Association of Turkey sits down to talk about price cuts, GMP requirements and the future of the Turkish pharma industry.
Pharma companies have weathered three rounds of price cuts in recent years, but there are signs that the worst may be over for now in Turkey.